Michael Schotsaert

Dr. Michael Schotsaert

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2020 in Nature
Verified
Journal Article
Closed access
PDF file
CMCésar Muñoz-Fontela
César Muñoz-Fontela
WDWilliam E. Dowling
William E. Dowling
SFSimon Gordon Paul Funnell
Simon Gordon Paul Funnell
PGPierre-S. Gsell
Pierre-S. Gsell
ARA. Ximena Riveros-Balta
A. Ximena Riveros-Balta
DBDan H. Barouch
Dan H. Barouch

24 July 2020 in Nature
Verified
Journal Article
Closed access
PDF file
LRLaura Riva
Laura Riva
SYShuofeng Yuan
Shuofeng Yuan
Xin YinXin Yin
Xin Yin
LMLaura Martin-Sancho
Laura Martin-Sancho
NMNaoko Matsunaga
Naoko Matsunaga
SCSumit K. Chanda
Sumit K. Chanda

21 January 2022 in Nature
Verified
Journal Article
Open access
PDF file
PHPeter J. Halfmann
Peter J. Halfmann
SIShun Iida
Shun Iida
KIKiyoko Iwatsuki-Horimoto
Kiyoko Iwatsuki-Horimoto
TMTadashi Maemura
Tadashi Maemura
MKMaki Kiso
Maki Kiso
YKYoshihiro Kawaoka
Yoshihiro Kawaoka
The recent emergence of B.1.1.529, the Omicron variant1,2, has raised concerns of escape from protection by vaccines and therapeutic antibodies. A key test for potential countermeasures against B.1.1.529 is their activity in preclinical rodent models of respiratory tract disease. Here, using the collaborative network of the SARS-CoV-2 Assessment of Viral Evolution (SAVE) programme of the National Institute of Allergy and Infectious Diseases (NIAID), we evaluated the ability of several B.1.1.529 isolates to cause infection and disease in immunocompetent and human ACE2 (hACE2)-expressing mice and hamsters. Despite modelling data indicating that B.1.1.529 spike can bind more avidly to mouse ACE2 (refs. 3,4), we observed less infection by B.1.1.529 in 129, C57BL/6, BALB/c and K18-hACE2 transgenic mice than by previous SARS-CoV-2 variants, with limited weight loss and lower viral burden in the upper and lower respiratory tracts. In wild-type and hACE2 transgenic hamsters, lung infection, clinical disease and pathology with B.1.1.529 were also milder than with historical isolates or other SARS-CoV-2 variants of concern. Overall, experiments from the SAVE/NIAID network with several B.1.1.529 isolates demonstrate attenuated lung disease in rodents, which parallels preliminary human clinical data.

26 February 2021 in Science
Verified
Journal Article
Open access
PDF file
KWKris White
Kris White
RRRomel Rosales
Romel Rosales
SYSoner Yildiz
Soner Yildiz
TKThomas Kehrer
Thomas Kehrer
LMLisa Miorin
Lisa Miorin
AGAdolfo Garcia-Sastre
Adolfo Garcia-Sastre
Hurting the virus by targeting the host: Many host proteins play a role in the life cycle of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and some are required for viral replication and translation. There are efforts toward finding drugs that target viral proteins, but a complementary approach is to target these required host proteins. White et al. explored the antiviral activity of the cyclic depsipeptide drug plitidepsin, which targets the hosts cell's translational machinery (see the Perspective by Wong and Damania). The authors show that in cells, the drug is substantially more potent than remdesivir against SARS-CoV-2, with limited cellular toxicity. Prophylactic treatment protected mice against SARS-CoV-2 infection, so further investigation of plitidepsin as a therapeutic is warranted. Science , this issue p. 926 ; see also p. 884

30 July 2021 in Science
Verified
Journal Article
Open access
PDF file
TTTia A. Tummino
Tia A. Tummino
VRVeronica V. Rezelj
Veronica V. Rezelj
BFBenoit Fischer
Benoit Fischer
AFAudrey Fischer
Audrey Fischer
MOMatthew James O'Meara
Matthew James O'Meara
BSBrian K. Shoichet
Brian K. Shoichet
Screening for drugs that don’t work: In the battle against COVID-19, drugs discovered in repurposing screens are of particular interest because these could be rapidly implemented as treatments. However, Tummino et al . deliver a cautionary tale, finding that many leads from such screens have an antiviral effect in cells through phospholipidosis, a phospholipid storage disorder that can be induced by cationic amphiphilic drugs (see the Perspective by Edwards and Hartung). There is a strong correlation between drug-induced phospholipidosis and inhibition of severe acute respiratory syndrome coronavirus 2 replication in cells. Unfortunately, drugs that have an antiviral effect in cells through phospholipidosis are unlikely to be effective in vivo. Screening out such drugs may allow a focus on drugs with better clinical potential. —VV

31 March 2022 in Nature
Verified
Journal Article
Closed access
PDF file
MDMarciela M. DeGrace
Marciela M. DeGrace
EGElodie Ghedin
Elodie Ghedin
Matthew FriemanMatthew Frieman
Matthew Frieman
Florian KrammerFlorian Krammer
Florian Krammer
AGAlba Grifoni
Alba Grifoni
MSMehul Suthar
Mehul Suthar